Researchers at the University of Turku, Finland, showed that the antibody treatment reactivates the immune defense in patients with advanced-stage cancer. The treatment alters the function of the body s phagocytes and facilitates extensive activation of the immune system.
Researchers at the University of Turku, Finland, showed that the antibody treatment reactivates the immune defense in patients with advanced-stage cancer.
The Company will invest in a combination of large, medium and smaller companies listed in the UK. We are not constrained by the weightings of any index; we focus instead on controlling absolute risk by diversifying on the basis of underlying company characteristics such as size, industry, economic sensitivity, clients and management. In normal circumstances up to half the portfolio will be invested in FTSE 100 companies; the remainder will be divided between small- and medium-sized companies. On occasions the Manager will buy shares listed overseas. The Manager may also invest a maximum of 15% in other listed trusts. It is a pleasure to report that, after a period of disappointing performance, the portfolio bounced back in the first half of the year, with NAV increasing by 33.0% against the benchmark s 18.5%. The previous financial year had started hopefully, only for those hopes to be dashed in March 2020 by the effects of the pandemi
17 May 2021 | 09:33am
StockMarketWire.com - Pharmaceutical company Faron Pharmaceuticals Oy said its bexmarilimab drug had shown promising anti-tumour activity in multiple advanced solid tumours.
Across the 141 evaluable patients, the phase I/II MATINS clinical trial of bexmarilimab showed that the median progression-free survival was 59 days and median overall survival was 129 days, the company said. Bexmarilimab s ability to increase survival in patients who have exhausted all treatment options is significant and demonstrates the importance of targeting myeloid cell control in the development of next generation immunotherapies, the company said.
At 9:33am: [LON:FARN] Faron Pharmaceuticals share price was 0p at 275p